TABLE 2.

ΔΔQTcF in ms (QT/QTc population).

Timepoint postdose (h)	Statistics	Rimegepant 75 mg	Rimegepant 300 mg	Moxifloxacin 400 mg
0.5	LS mean	1.2	−0.1	8.1
	90% CI	(−1.05, 3.38)	(−2.29, 2.12)	(5.90, 10.37)
1.0	LS mean	0.6	0.1	11.6
	90% CI	(−1.58, 2.80)	(−2.07, 2.27)	(9.37, 13.78)
1.5	LS mean	−0.7	0.9	12.0
	90% CI	(−2.54, 1.22)	(−0.94, 2.79)	(10.10, 13.89)
2	LS mean	−1.4	−0.5	12.8
	90% CI	(−3.39, 0.55)	(−2.44, 1.47)	(10.80, 14.78)
2.5	LS mean	−0.2	0.5	12.8
	90% CI	(−2.42, 2.06)	(−1.72, 2.72)	(10.50, 15.00)
3	LS mean	0.5	0.7	13.3
	90% CI	(−1.62, 2.54)	(−1.33, 2.79)	(11.23, 15.42)
3.5	LS mean	2.0	1.1	14.1
	90% CI	(0.01, 4.06)	(−0.87, 3.16)	(12.10, 16.20)
4	LS mean	1.0	0.9	13.5
	90% CI	(−1.16, 3.10)	(−1.26, 2.98)	(11.33, 15.64)
5	LS mean	0.9	1.5	11.1
	90% CI	(−2.27, 4.15)	(−1.66, 4.69)	(7.88, 14.32)
6	LS mean	1.2	0.9	9.4
	90% CI	(−1.86, 4.27)	(−2.17, 3.92)	(6.27, 12.47)
12	LS mean	−0.3	−0.9	7.5
	90% CI	(−2.85, 2.30)	(−3.44, 1.68)	(4.89, 10.10)
24	LS mean	0.9	1.6	6.7
	90% CI	(−1.51, 3.31)	(−0.80, 3.98)	(4.23, 9.10)

Abbreviations: CI, confidence interval; LS, least squares; ΔΔQTcF, placebo‐corrected change‐from‐baseline in Fridericia corrected QT interval.